about
FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapiesHyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83BRole of bone-anabolic agents in the treatment of breast cancer bone metastasesInfluence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer preventionNetwork-level effects of kinase inhibitors modulate TNF-α-induced apoptosis in the intestinal epitheliumBiological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agentRSK in tumorigenesis: connections to steroid signaling.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Endothelial cell-derived interleukin-6 regulates tumor growth.Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.Evaluation of ERG responsive proteome in prostate cancerRational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma.Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancersmTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitorPreclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.Rational Combinations of Targeted Agents in AMLA novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways.Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β₃ affinity modulation.Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycinIntegrative analysis of cancer genes in a functional interactome.TMEFF2 modulates the AKT and ERK signaling pathwaysRegression of prostate cancer xenografts by RLIP76 depletion.Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibodyRapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cellsDepletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs.Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.New agents for AML and MDS.PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension.Somatic evolution of head and neck cancer - biological robustness and latent vulnerability.
P2860
Q24292888-CF3E880B-FDCE-47E9-95C6-1F272D803874Q24314709-600E680F-DEC7-4405-AAAA-B0B7DDE92A03Q26822732-B8AB18E6-992A-4B73-9375-278CF302559DQ28258801-A7F7A7D1-AD30-49A6-8BA6-7E1730E4912BQ28390885-DFF79653-9777-4850-A278-B5E020147187Q28486289-2C7CACB1-4D76-4510-AA0E-C547E4A3D51FQ30433106-B70062DD-DDED-4A4D-B490-3FA46441330EQ33439312-EA302786-8525-488E-905A-3B4B248A78DAQ33592677-C5CBC8E3-E228-4953-B0DE-0DFA51D41A69Q33688908-D50E8256-EF1B-465F-A8F5-B136BD06DB4AQ33822319-AD4ADCE3-F50D-4ED5-902D-6DE013C90B45Q33840360-3BE1D724-9943-4A80-8F3B-B832A54CB7A5Q33842810-5102D6A5-FD16-4D9B-A30F-7CA6723A5338Q33861319-28CE3737-03BB-46ED-B1F1-E02B9DB4DE92Q34233838-78A5DFCD-E33C-436F-85CA-4A45CE0D4C2CQ34689078-421FFE68-5606-4E9D-A90D-53AAA09AA0CDQ34768262-564EA4B5-67D3-4C06-98A9-E897A26CDB45Q34970844-6907F77D-F0C4-407E-85B0-226B2264B1E4Q35086777-3AA68049-A2E6-48F9-814E-8D6737B9F30BQ35207897-BFF94DCA-4FB4-4BBD-A54E-3B23F963015BQ35589601-C5BB71E9-A563-4D05-BF62-066F2C0E6909Q35737974-509CA214-3D4E-44D8-B087-959E610BFFF9Q35750491-6FAA527E-D3A9-4366-9986-4AFE14506A36Q35798191-2EE3491A-7749-4283-9523-9803C15AA30CQ36124790-2F1E47C3-A8C5-4991-81E1-B48ECF9010F8Q36144821-BA228E9B-EF9C-48BD-ADBA-B1A90E222B25Q36166788-D3EBF2F4-2EE6-4BCD-B7EB-E4BB4BE8714CQ36174463-55FB06C4-EF49-498E-AD27-17E64AFA097FQ37054427-76CFC75D-8296-46EB-B5F5-C7711BC03634Q37059535-91124BC9-71C0-4694-94BC-8D52FBBA4C61Q37194622-571BACB1-BE37-4EEB-BAD9-409B8D60BB5EQ37227994-E6E15E51-3C23-4F91-AEC6-5043C02EF7D6Q37278425-E28D9EEF-1BBB-485D-8126-B3FE19710256Q37301601-867F11E1-39EB-4CF9-AD8B-7019847C2533Q37312692-E2AAAD2D-C579-4ACB-9A63-639E5268D436Q37384464-0492C232-4C80-4780-8DAD-6EAC0BC5E52FQ37474602-A3784A60-ACDF-4303-89D7-72E6162BFC02Q37655023-AD4F09A0-C15B-4C4C-8290-61CBA14285CDQ37702986-F618AAFF-4EA0-4749-BD5B-EB6852E8D3C1Q38061224-D8D022F4-48ED-4A48-BB55-BA79EB1068E9
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cotargeting survival signaling pathways in cancer.
@en
Cotargeting survival signaling pathways in cancer.
@nl
type
label
Cotargeting survival signaling pathways in cancer.
@en
Cotargeting survival signaling pathways in cancer.
@nl
prefLabel
Cotargeting survival signaling pathways in cancer.
@en
Cotargeting survival signaling pathways in cancer.
@nl
P2860
P356
P1476
Cotargeting survival signaling pathways in cancer.
@en
P2093
Steven Grant
P2860
P304
P356
10.1172/JCI36898
P407
P577
2008-09-01T00:00:00Z